Amgen Reports Positive Topline Phase 3 Results For Subcutaneous Tepezza In Thyroid Eye Disease

April 6 (Reuters) - Amgen Inc AMGN.O:

• AMGEN: ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA IN ADULTS WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE

• AMGEN: PHASE 3 TEPEZZA OBI TRIAL MET PRIMARY & KEY SECONDARY ENDPOINTS

• AMGEN: PHASE 3 TEPEZZA TRIAL OVERALL SAFETY RESULTS GENERALLY CONSISTENT WITH KNOWN SAFETY PROFILE OF TEPEZZA IV

• AMGEN: PHASE 3 TEPEZZA TRIAL SHOWED CLINICALLY MEANINGFUL REDUCTION IN PROPTOSIS